PKA

PKA Inhibitor Fragment (6-22) amide TFA (PKA Inhibitor Fragment (6-22) amide TFA) is a highly potent inhibitor of cAMP-dependent protein kinase A (PKA) with a Ki of 2.8 nM and reverses the pain-relieving effects of low levels of morphine in mice.

PKA inhibitor fragment (6-22) amide Acetate is a synthetic peptide which selectively inhibits PKA activity by binding to its substrate site (IC50 < 2 nM).

CREBtide acetate is a synthetic substrate for PKA (Km=3.9 μM), which is based on the phosphorylation sequence in d-CREB (cAMP response element binding protein).

PKI (5-24) Acetate is a high affinity PKA inhibitor (Ki = 2.3 nM).

Malantide acetate is a dodecapeptide phosphorylated by cyclic AMP-dependent protein kinase (PKA), and increases PKA activity.Malantide is a synthetic peptide that is phosphorylated by PKA and is used to measure PKA activity in vitro.

PKI 14-22 amide, myristoylated Acetate inhibit cAMP-dependent protein kinase (PKA) and blocks hyperalgesia produced by spinal administration of 8-bromo-cAMP.

PKG Substrate acetate is a selective substrate for cGMP-dependent protein kinase (PKG).PKG Substrate is a selective substrate for protein kinase G (PKG) with a strong preference for PKG Iα (Km = 59 μM) over PKG II (Km = 305 μM).

PKG inhibitor peptide TFA (82801-73-8 free base) is an inhibitor of ATP-competitive cGMP-dependent protein kinase (PKG).

Kemptide is a synthetic heptapeptide, acting as a substrate for cAMP-dependent protein kinase (PK).

PKItide demonstrates an inhibitory concentration 50 (IC50) of 0.2 μM against cAMP-dependent protein kinase (cAMP-PK) [1].

DT-2 acetate, a selective cGMP-dependent protein kinase (PKG) inhibitor, is a mouse monoclonal antibody targeting canine thymocytes.DT-2 acetate inhibits PKG-catalyzed phosphorylation, reverses 8-Br-cGMP-induced expansion, and can be used to study immune disorders.

H1-7 (histone H1 phosphorylation site), a synthetic polypeptide, serves as a PKA substrate and demonstrates utility in various PKA substrate applications [1] [2].

MLCK inhibitor peptide 18 acetate is a selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.

PKI (14-24)amide TFA, a potent inhibitor of Protein Kinase A (PKA), significantly reduces cyclic AMP-dependent protein kinase activity within cellular homogenates, as evidenced by research findings [1] [2].

PKI (14-24)amide is a potent inhibitor of Protein Kinase A (PKA), effectively inhibiting cyclic AMP-dependent protein kinase activity in cell homogenates [1] [2].

CREBtide is a synthetic substrate for PKA (Km=3.9 µM), which is based on the phosphorylation sequence in d-CREB (cAMP response element binding protein).

Stearated form of the peptide Ht-31. Inhibits the interaction between the RII subunits of cAMP-dependent PKA and A-kinase anchoring protein (AKAP) in cell extracts. Cell permeable.

st-Ht31, a cell-permeable stearated peptide derived from the amphipathic helix domain of A-kinase anchoring proteins (AKAPs), effectively binds protein kinase A (PKA), impacting PKA's cellular interactions without altering its activity. Specifically, at a 50 µM concentration, it reduces PKA's membrane anchoring in BHK-21 fibroblast reporter assays. Moreover, st-Ht31 at concentrations of 1 and 3 µM decreases both capacitance and hyperactivation in mouse sperm, thereby inhibiting in vitro fertilization. Additionally, at 50 µM, this compound facilitates cholesterol export in BHK-21 cells and RAW 264.7 macrophages expressing ATP-binding cassette transporter 1 (ABCA1), showcasing its multifaceted cellular impacts.

Malantide TFA, a synthetic dodecapeptide, originates from the phosphorylation site targeted by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Exhibiting a high specificity for PKA with a Michaelis constant (Km) of 15 μM, this compound demonstrates more than 90% inhibition of substrate phosphorylation in the presence of protein inhibitor (PKI) across various rat tissue extracts [1]. Moreover, Malantide TFA acts as an effective substrate for Protein Kinase C (PKC) with a Km of 16 μM [2].

PKI (5-24), amide (IP20-amide) is a potent inhibitor of cAMP-dependent protein kinase (PKA) with an inhibition constant (K i) of 2.3 nM [1]. This 20-residue peptide mirrors the active segment of the heat-stable inhibitor protein specific to PKA, showcasing significant inhibitory efficacy.

STAD-2 is a cell permeable akap disruptor, selectively binding to pka-rii and blocking the interaction of pka-ri with akap

Kemptide (Phospho-Ser5) is a phosphoreceptor peptide that serves as a specific substrate for cAMP-dependent protein kinase (PKA).

Malantide is a dodecapeptide phosphorylated by cyclic AMP-dependent protein kinase (PKA), and increases PKA activity.Malantide is a synthetic peptide that is phosphorylated by PKA and is used to measure PKA activity in vitro.

Tat-AKAP79 (326-336) is a peptide that links the HIV-1 Tat protein transduction domain with an 11-amino acid sequence from A-kinase anchor protein 79 (AKAP79). This compound effectively inhibits the activation-induced sensitization by protein kinase A (PKA) or PKC of the transient receptor potential vanilloid 1 (TRPV1) at a concentration of 200 µM in isolated rat dorsal root ganglion (DRG) neurons. Additionally, it mitigates nocifensive behavior in mice elicited by formalin or phorbol 12-myristate 13-acetate (PMA014), enhances latency for paw withdrawal from radiant heat, and raises the mechanical threshold force required for paw withdrawal in a carrageenan-induced mouse model of inflammatory pain.

Urocortin II, mouse, is a selective and potent endogenous peptide agonist for the type-2 corticotropin-releasing factor (CRF2) receptor, displaying K_i values of 0.66 nM for CRFR2 and >100 nM for CRFR1, signifying its high specificity. It engages CRF2 receptors through mechanisms dependent on cAMP/PKA and Ca2+/CaMKII. Additionally, Urocortin II, mouse is localized in specific regions of the central nervous system, influencing central neurons that process visceral sensory information and regulate autonomic functions [1] [2] [3].

Phosphate acceptor peptide acts as a substrate for cAMP-dependent protein kinase (PKA) and serves as a weak inhibitor of protein kinase C (PKC) [1].

PKI(5-22)amide, an active inhibitory fragment of the cyclic AMP-dependent protein kinase (PKA) inhibitor, effectively prevents PKA activation. However, it does not reduce the homologous desensitization of CRF1 receptors [1] [2].

PKI(5-24) TFA is a synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase) with potent and competitive inhibition properties, exhibiting a K i of 2.3 nM. It corresponds to residues 5-24 of the natural heat-stable protein kinase inhibitor [1][2].

Selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.

Competitive inhibitor of cGMP-dependent protein kinase (PKG); analog of a substrate peptide corresponding to a phosphorylation site of histone H2B. Competes with synthetic substrates (Ki = 86 mM) but does not inhibit phosphorylation of intact histones by

Amylin (AMY3) receptor antagonist. Inhibits andrenomedulin-stimulated cAMP production in vitro. Protects against oligomeric Aβ-induced increase in intracellular Ca2+, activation of PKA, MAPK, Akt and cFOS and cell death in neuronal cell culture. Blocks el

Cys-Kemptide, a cysteine-terminated substrate peptide, is utilized for measuring protein kinase A (PKA) activity [1].

PKI 14-22 amide, myristoylated TFA is a potent inhibitor of cAMP-dependent protein kinase A (PKA) that diminishes IgG-mediated phagocytic response and inhibits neutrophil adhesion [1].

High affinity PKA inhibitor (Ki = 2.3 nM).

AKAP disruptor. Selectively binds PKA-RI with high affinity (KD values are 6.2 and 12.1 nM for the RIα and β subunits, respectively) and blocks its interaction with AKAP. Inhibits type I PKA-mediated phosphorylation in live cells. Cell permeable.